While JAK2 mutations associated with ALL are predicted to disrupt JH2-mediated autoinhibition, these mutations alone are not sufficient to constitutively activate JAK2 (Hammaren et al., 2019a; Hammaren et al., 2019b). The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.